Ingebrigtsen Truls S, Marott Jacob L, Vestbo Jørgen, Nordestgaard Børge G, Hallas Jesper, Lange Peter
Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark; The Copenhagen General Population Study, University of Copenhagen, Copenhagen, Denmark.
Respirology. 2015 Jan;20(1):101-7. doi: 10.1111/resp.12420. Epub 2014 Oct 8.
We tested the hypothesis that gastro-esophageal reflux disease is a risk factor for exacerbations in individuals with chronic obstructive pulmonary disease (COPD).
Among 9622 participants in the Copenhagen City Heart Study, we identified 1259 individuals with COPD and information on gastro-esophageal reflux disease and the regular use of acid inhibitory treatment. These individuals were followed for 5 years with regard to medically treated COPD exacerbations, which we defined as a short course treatment with oral corticosteroids alone or in combination with antibiotics. We applied a multivariable Cox regression analysis with adjustment for well-established risk factors associated with COPD exacerbations or gastro-esophageal reflux disease, including COPD severity, and symptoms.
Individuals with COPD and gastro-esophageal reflux disease had more chronic bronchitis (31 vs 21%, P = 0.004), more breathlessness (39 vs 22%, P < 0.001), and more of them had a history of respiratory infections (6.8 vs 1.4%, P < 0.001) than individuals with COPD but without gastro-esophageal reflux disease. Among individuals with COPD and gastro-esophageal reflux disease, those who did not use acid inhibitory treatment regularly had an increased risk of COPD exacerbations during follow-up, hazards ratio (HR): HR = 2.7 (1.3-5.4, P = 0.006). Individuals with gastro-esophageal reflux disease, using acid inhibitory treatment regularly did not have an increased risk of exacerbations, HR = 1.2 (0.6-2.7, P = 0.63).
Gastro-esophageal reflux disease was associated with an increased risk of medically treated exacerbations of COPD, but only in those individuals who did not use acid inhibitory treatment regularly.
我们检验了如下假设,即胃食管反流病是慢性阻塞性肺疾病(COPD)患者病情加重的一个危险因素。
在哥本哈根市心脏研究的9622名参与者中,我们确定了1259名患有COPD的个体,并获取了有关胃食管反流病及酸抑制治疗常规使用情况的信息。对这些个体进行了为期5年的随访,观察经药物治疗的COPD病情加重情况,我们将其定义为单独使用口服糖皮质激素或联合使用抗生素的短期治疗。我们应用多变量Cox回归分析,并对与COPD病情加重或胃食管反流病相关的公认危险因素进行了校正,包括COPD严重程度和症状。
与无胃食管反流病的COPD患者相比,患有COPD且有胃食管反流病的个体慢性支气管炎更多(31%对21%,P = 0.004),呼吸急促更多(39%对22%,P < 0.001),且有呼吸道感染史的更多(6.8%对1.4%,P < 0.001)。在患有COPD且有胃食管反流病的个体中,未常规使用酸抑制治疗的个体在随访期间COPD病情加重的风险增加,风险比(HR):HR = 2.7(1.3 - 5.4,P = 0.006)。常规使用酸抑制治疗的胃食管反流病个体病情加重风险未增加,HR = 1.2(0.6 - 2.7,P = 0.63)。
胃食管反流病与经药物治疗的COPD病情加重风险增加相关,但仅在那些未常规使用酸抑制治疗的个体中如此。